Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report)'s stock price shot up 7.9% during trading on Monday . The stock traded as high as $30.00 and last traded at $24.80. 2,625,472 shares traded hands during trading, a decline of 81% from the average session volume of 13,968,843 shares. The stock had previously closed at $22.99.
Regencell Bioscience Trading Down 19.8%
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Regencell Bioscience stock. Greenfield Savings Bank acquired a new stake in Regencell Bioscience Holdings Limited (NASDAQ:RGC - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,000 shares of the company's stock, valued at approximately $187,000. 0.13% of the stock is currently owned by institutional investors.
About Regencell Bioscience
(
Get Free Report)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
Recommended Stories
Before you consider Regencell Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regencell Bioscience wasn't on the list.
While Regencell Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
